CN109982998A - 白蛋白结合psma抑制剂 - Google Patents

白蛋白结合psma抑制剂 Download PDF

Info

Publication number
CN109982998A
CN109982998A CN201780071927.6A CN201780071927A CN109982998A CN 109982998 A CN109982998 A CN 109982998A CN 201780071927 A CN201780071927 A CN 201780071927A CN 109982998 A CN109982998 A CN 109982998A
Authority
CN
China
Prior art keywords
compound
formula
group
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071927.6A
Other languages
English (en)
Chinese (zh)
Inventor
C.伯克曼
C.乔伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Targeted Technology LLC
Original Assignee
Cancer Targeted Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology LLC filed Critical Cancer Targeted Technology LLC
Publication of CN109982998A publication Critical patent/CN109982998A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780071927.6A 2016-11-23 2017-11-24 白蛋白结合psma抑制剂 Pending CN109982998A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
CN109982998A true CN109982998A (zh) 2019-07-05

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071927.6A Pending CN109982998A (zh) 2016-11-23 2017-11-24 白蛋白结合psma抑制剂

Country Status (8)

Country Link
US (1) US11147889B2 (enExample)
EP (1) EP3544960A1 (enExample)
JP (1) JP7167021B2 (enExample)
CN (1) CN109982998A (enExample)
BR (1) BR112019010206A2 (enExample)
CA (1) CA3043619A1 (enExample)
MX (1) MX2019005742A (enExample)
WO (1) WO2018098390A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
CN116217505A (zh) * 2023-03-17 2023-06-06 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079906A1 (en) * 2017-10-22 2019-04-25 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
WO2020102348A1 (en) 2018-11-14 2020-05-22 Stephen Dimagno Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020210909A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
KR20220024595A (ko) 2019-06-21 2022-03-03 프로빈셜 헬스 서비시즈 오쏘리티 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물
CN115210240A (zh) 2020-03-04 2022-10-18 日本医事物理股份有限公司 化合物及放射性标记化合物
US20230165979A1 (en) * 2020-05-06 2023-06-01 Cornell University Copper-containing theragnostic compositions and methods of use
MX2023006483A (es) * 2020-12-04 2023-07-20 Univ California Terapia radionuclidica de receptores peptidicos.
CA3201655A1 (en) * 2020-12-16 2022-06-23 Francois Benard Radiolabeled compounds targeting the prostate-specific membrane antigen
EP4303213A4 (en) * 2021-03-04 2024-09-18 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034494A1 (en) * 2011-08-05 2013-02-07 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
CN105849568A (zh) * 2013-11-14 2016-08-10 恩多塞特公司 用于正电子发射断层术的化合物
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
PL3964502T3 (pl) * 2009-03-19 2024-10-28 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
WO2017054907A1 (en) * 2015-09-30 2017-04-06 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
ES2877572T3 (es) * 2016-03-22 2021-11-17 Univ Johns Hopkins Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata
KR102513698B1 (ko) * 2016-06-23 2023-03-23 코넬 유니버시티 종양 사멸에 영향을 주기 위한 이중 표적화 작제물
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034494A1 (en) * 2011-08-05 2013-02-07 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
CN105849568A (zh) * 2013-11-14 2016-08-10 恩多塞特公司 用于正电子发射断层术的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HASSAN M. SHALLAL等: ""Heterobivalent Agents Targeting PSMA and Integrin-αvβ3"", 《BIOCONJUGATE CHEMISTRY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505A (zh) * 2023-03-17 2023-06-06 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Also Published As

Publication number Publication date
WO2018098390A1 (en) 2018-05-31
CA3043619A1 (en) 2018-05-31
US20200061218A1 (en) 2020-02-27
JP2019535754A (ja) 2019-12-12
US11147889B2 (en) 2021-10-19
JP7167021B2 (ja) 2022-11-08
EP3544960A1 (en) 2019-10-02
MX2019005742A (es) 2019-09-13
BR112019010206A2 (pt) 2019-09-03

Similar Documents

Publication Publication Date Title
CN109982998A (zh) 白蛋白结合psma抑制剂
CN103874512B (zh) 选择性递送分子及使用方法
JP5848332B2 (ja) 光学造影および療法のタンデムのための官能性架橋型ナノ構造物
AU2013303233C1 (en) Prostate specific antigen agents and methods of using same for prostate cancer imaging
JP7324763B2 (ja) 分子イメージングのための二重標識プローブ及びその使用
CN103687854A (zh) 碳酸酐酶靶向剂及其使用方法
BR112019012986A2 (pt) imageamento de tumores e de células imunes com base na expressão de pd-l1
EA037512B1 (ru) Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты
JP2022176252A (ja) キレート化されたｐｓｍａ阻害剤
JP2023145464A (ja) 分子イメージングのための二重標識プローブ及びその使用
US20210128731A1 (en) Nanoparticles for boron neutron capture therapy and for diagnosing, detecting, and treating cancer
US20240009314A1 (en) Compositions and methods for targeting tumor-associated macrophages
JP2016528299A (ja) ビタミンｂ１２および内因子を含む組成物およびその使用方法
US20210113715A1 (en) Targeted nanoparticles for diagnosing, detecting and treating cancer
Zhang et al. Visualizing tumors in real time: a highly sensitive PSMA probe for NIR-II imaging and intraoperative tumor resection
JP2023554079A (ja) リガンド及びそれらの使用
JP2020531509A (ja) 炭酸脱水酵素陽性がんを標的とするｆｂｓａ系治療および放射性造影複合体
JP2018518509A (ja) 白金化合物、組成物及びその使用
US20150217006A1 (en) Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
US20210121569A1 (en) Nanotherapeutic systems and methods using particle-driven photodynamic therapy (pdt)
CN110382010A (zh) 铋-钆纳米颗粒
Im et al. Porphyrin-Based Brain Tumor-Targeting Agents:[64Cu] Cu-porphyrin and [64Cu] Cu-TDAP
US20250082795A1 (en) Combinations of imaging agent conjugates and application thereof
KR20190135500A (ko) 개질된 mri 조영제 및 이의 용도
CN102020768B (zh) 一种99mTc配合物、其制备方法、中间体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190705

WD01 Invention patent application deemed withdrawn after publication